Corporate ProfileEdge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.
We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More |  | Stock InformationIR Contact
|
Upcoming Events
There are currently no events scheduled. |
Presentation
Date | Title | February 15, 2018 | |
|
Lastest News
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page
Email Page
RSS Feeds
Email Alerts
IR Contacts